Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. |
| 2005 Release |
 |
| December 27, 2005 |
|
Eisai Receives confirmation that Aricept (donepezil hydrochloride), Orodispersible Tablet has successfully completed the Mutual Recognition Procedure in the 12 EU countries
|
|
| December 26, 2005 |
|
New Drug Application for Rheumatoid Arthritis Drug Adalimumab (D2E7) Submitted in Japan
|
|
| December 22, 2005 |
|
Eisai applies for a new indication of Severe Alzheimer's disease for Aricept (donepezil hydrochloride) in Japan
|
|
| December 19, 2005 |
|
Eisai Resubmits the sNDA Application for Aricept for Treatment of Severe Alzheimer's Disease
|
|
| December 12, 2005 |
|
Eisai Presented Phase II Data on E7389, a Potential New Therapy for the treatment of Breast Cancer, in US Conference
|
|
| December 8, 2005 |
|
Eisai Commences U.S. Legal Action over Aricept ANDA Filing
|
|
| November 29, 2005 |
|
Part of a news report on cash dividends of Eisai Co., Ltd.
|
|
| November 25, 2005 |
|
Termination of Marketing Alliance on Rulid Tablets 150mg
|
|
| November 18, 2005 |
|
Eisai Resubmits NDA Application for the Anti-epilepsy Drug Rufinamide
|
|
| November 1, 2005 |
|
SELBELLE Tablets Launched by Eisai Medication that Improves Stomach Function by Protecting Gastric Mucosa from Stomach Acid
|
|
| October 28, 2005 |
|
Eisai Announces About the sNDA Application for ARICEPT for Treatment of Severe Alzheimer's Disease
|
|
| October 28, 2005 |
|
Eisai Licenses E6020 Vaccine Adjuvant to Sanofi Pasteur SA
|
|
| October 11, 2005 |
|
Eisai and TorreyPines Therapeutics Enter Into a New Alliance Contract Regarding a New Genetic Research Program for Alzheimer's Disease
|
|
| September 29, 2005 |
|
Dainippon and Eisai Signed Licensing Agreement for A Potential New Treatment for Diabetic Neuropathy
|
|
| September 28, 2005 |
|
Eisai Announces Exclusive In-License of All U.S. Promotional Rights for FRAGMIN , an Injectable Anti-Clotting Agent
|
|
| September 22, 2005 |
|
Lost Hard Disk Drive Containing Personal Information in Japan
|
|
| September 13, 2005 |
|
Eisai Submits New Drug Application for the Anti-epileptic Agent Rufinamide in the United States
|
|
| September 12, 2005 |
|
Notice Concerning The Change of The Distribution Company from Aventis Pharma to Eisai for “Actonel 2.5mg Tablets” of Ajinomoto
|
|
| September 1, 2005 |
|
Eisai Submitted Application to FDA for ARICEPT for Treatment of Severe Alzheimer's Disease
|
|
| August 29, 2005 |
|
Eisai Announces Successful Results in a Phase II Study of E5564 (eritoran) for Treatment of Severe Sepsis
|
|
| August 26, 2005 |
|
Eisai Announces Strategic Alliance With BioArctic Neuroscience To Develop Immunotherapy For Alzheimer's Disease
|
|
| August 24, 2005 |
|
Sanko Junyaku and Eisai Initiate Co-promoting Yamasa Corporation's Diagnostic Kit for Interstitial Pneumonia, SP-D EIA KIT YAMASA
|
|
| August 22, 2005 |
|
Eisai Launches Antiasthmatic, Antitussive and Expectorant, ASTHPHYLLIN S Tablets
|
|
| August 2, 2005 |
|
Eisai Receives Approval for Cleactor Inj for Acute Pulmonary Embolism in Japan
|
|
| July 14, 2005 |
|
Eisai Announces Establishment of a Pharmaceuticals Marketing Subsidiary in Sweden
|
|
| July 1, 2005 |
|
Notice Concerning Stock Options (Stock Acquisition Rights) Including the Amount Paid In Upon the Exercise of Stock Options
|
|
| June 27, 2005 |
|
Eisai Announces Launch of Zonegran(zonisamide), Treatment For Epilepsy In the U.K. and Germany
|
|
| June 24, 2005 |
|
Notice on Allotment of Stock Options (Stock Acquisition Rights)
|
|
| June 9, 2005 |
|
Eisai Announces Establishment of its Pharmaceuticals Marketing Subsidiary in Switzerland
|
|
| May 30, 2005 |
|
Concerning Theft of a Computer of Eisai's Subsidiary Sanko Junyaku Containing Personal Information
|
|
| May 24, 2005 |
|
Eisai Receives Marketing Authorization Approval for Aricept Evess (donepezil hydrochloride), Orodispersible Tablet in the U.K.
|
|
| May 16, 2005 |
|
Notice on Providing Stock Options in the Form of New Stock Issuance
|
|
| April 11, 2005 |
|
Eisai and Abbott Signed a Joint Development Agreement for new indication, psoriasis, of anti-rheumatic agent D2E7 (adalimumab)
|
|
| April 1, 2005 |
|
Eisai Announces the Merger of Two Subsidiaries in Taiwan
|
|
| March 30, 2005 |
|
Eisai Announces Submission of Marketing Authorization Application of the Anti-epileptic Agent Inovelon in Europe
|
|
| March 29, 2005 |
|
Dainippon Pharmaceutical and Eisai Conclude Agreement for the Development, Manufacture and Marketing of the Anti-Epileptic Agent Zonisamide in Asia
|
|
| March 24, 2005 |
|
Eisai files Lawsuits against Companies Selling Generic Products of Eisai's Selbex Capsule 50 mg based on the Unfair Competition Prevention Law in the Japanese Market
|
|
| March 18, 2005 |
|
Eisai and TorreyPines Therapeutics Announces Second Major Discovery Alliance
|
|
| March 16, 2005 |
|
Eisai Receives Zonegran Marketing Authorization
Granted by European Commission
|
|
| March 15, 2005 |
|
Eisai Files Application for A New Indication for PARIET (rabeprazole sodium) in Japan for H. Pylori Eradication Indication
|
|
| February 25, 2005 |
|
Eisai Announces the Intermediate Analysis of Anti-osteoporosis Treatment Post-marketing Research to Investigate the Benefits of Menatetrenone As Part of the Ministry of Health, Labour and Welfare's Pharmacoepidemiological Drug Review Program
|
|
| February 25, 2005 |
|
US FDA Tentative Approval for ANDA filing of Donepezil Hydrochloride
|
|
| February 24, 2005 |
|
Eisai Announces Establishment of its Pharmaceuticals
Marketing Subsidiary in Italy
|
|
| February 2, 2005 |
|
Notice Concerning Revision of Year End Dividend Forecast For Fiscal Year Period (93rd Company Fiscal Period) Ending March 2005
|
|
| February 2, 2005 |
|
Transfer of Marketing Rights of ACE Inhibitor Inhibace from Eisai to Chugai
|
|
| January 18, 2005 |
|
ACIPHEX/ PARIET Expanded Manufacturing Facility Completed at Misato Plant
|
|
| | | |
